Nalaganje...
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
OBJECTIVE: To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. BACKGROUND: Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene‐related peptide (CGRP) and has demonstrated efficacy in reducing migraine h...
Shranjeno v:
| izdano v: | Headache |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6221112/ https://ncbi.nlm.nih.gov/pubmed/30341990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13427 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|